Compare WYNN & MEDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WYNN | MEDP |
|---|---|---|
| Founded | 2002 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.2B | 11.7B |
| IPO Year | 2002 | 2016 |
| Metric | WYNN | MEDP |
|---|---|---|
| Price | $102.17 | $422.73 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 15 | 12 |
| Target Price | $142.73 | ★ $473.17 |
| AVG Volume (30 Days) | ★ 1.2M | 449.8K |
| Earning Date | 05-07-2026 | 04-22-2026 |
| Dividend Yield | ★ 0.96% | N/A |
| EPS Growth | N/A | ★ 20.98 |
| EPS | 1.04 | ★ 4.28 |
| Revenue | ★ $6,717,660,000.00 | N/A |
| Revenue This Year | $6.49 | $13.19 |
| Revenue Next Year | $4.58 | $7.75 |
| P/E Ratio | ★ $34.05 | $100.52 |
| Revenue Growth | ★ 10.67 | N/A |
| 52 Week Low | $82.63 | $284.48 |
| 52 Week High | $134.72 | $628.92 |
| Indicator | WYNN | MEDP |
|---|---|---|
| Relative Strength Index (RSI) | 42.81 | 39.63 |
| Support Level | $96.26 | $382.68 |
| Resistance Level | $106.27 | $477.04 |
| Average True Range (ATR) | 3.16 | 16.56 |
| MACD | -0.27 | -2.21 |
| Stochastic Oscillator | 22.60 | 31.48 |
Wynn Resorts operates luxury casinos and resorts. The company was founded in 2002 by Steve Wynn, the former CEO. The company operates four megaresorts: Wynn Macau and Encore in Macao and Wynn Las Vegas and Encore in Las Vegas. Cotai Palace opened in August 2016 in Macao, and Encore Boston Harbor in Massachusetts opened June 2019. We expect the company to continue to build nongaming attractions in Macao over the next few years. We model Wynn's managed integrated resort in the United Arab Emirates to open in 2027. The company received 49% and 51% of its 2025 prepandemic EBITDA from Macao and the US, respectively.
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.